Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Non-Current Liabilities (2022 - 2025)

Vivos Therapeutics has reported Total Non-Current Liabilities over the past 3 years, most recently at $25.4 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities changed N/A to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $25.4 million for FY2025, N/A changed from the prior year.
  • Total Non-Current Liabilities was $25.4 million for Q4 2025 at Vivos Therapeutics, up from $21.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $25.4 million in Q4 2025 and troughed at $8.4 million in Q1 2022.
  • The 3-year median for Total Non-Current Liabilities is $9.7 million (2023), against an average of $14.8 million.
  • The largest YoY upside for Total Non-Current Liabilities was 4.17% in 2023 against a maximum downside of 4.17% in 2023.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $8.4 million in 2022, then grew by 15.26% to $9.7 million in 2023, then skyrocketed by 161.88% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Total Non-Current Liabilities are $25.4 million (Q4 2025), $21.7 million (Q3 2025), and $20.1 million (Q2 2025).